Zdrowie i gospodarka · 21/06/2024

FDA Issues Final Guidance on Delaying, Denying, Limiting, or Refusing Drug or Device Inspections

The FDA has released a final guidance document outlining the circumstances under which a drug or device manufacturer may be deemed adulterated if they delay, deny, limit, or refuse an FDA inspection, as mandated by the FDA Reauthorization Act of 2017.